In the most recent trading session, Johnson & Johnson (JNJ) closed at $143.85, indicating a -1.89% shift from the previous trading day.
The U.S. Food and Drug Administration has declined to approve an injectable version of Johnson & Johnson's drug Rybrevant for a type of lung cancer, the drugmaker said on Monday.
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Johnson & Johnson (NYSE: JNJ) is rewarding its shareholders once again with a quarterly dividend of $1.24, payable on Tuesday, Dec.
In the most recent trading session, Johnson & Johnson (JNJ) closed at $150.47, indicating a -1.24% shift from the previous trading day.
Johnson & Johnson JNJ announced that it has filed two supplemental biologics license applications (sBLA) seeking expanded use of its drug Tremfya in pediatric patients.
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Johnson & Johnson offers investors an effective combination of dividend income and dividend growth, evidenced by its Dividend Yield [TTM] of 3.13% and 5-Year Dividend Growth Rate [CAGR] of 5.61%. The company from the Pharmaceuticals Industry, which has an Aaa credit rating from Moody's, can serve as a strategically important core-position within your dividend portfolio. Allocating the largest proportion of your dividend portfolio to Johnson & Johnson can position your portfolio for reduced volatility and help to decrease its overall risk level.
Checking a company's vital signs before investing in its stock for dividend income is essential. If the underlying company isn't financially healthy, its dividend probably won't last very long.
If approved, JNJ's Tremfya will be the first IL-23 inhibitor to offer a choice of subcutaneous or intravenous use as induction treatment in ulcerative colitis.
2 Unstoppable Dividend Stocks to Buy Now With $500
Dividend Kings, like Coca-Cola, Johnson & Johnson, and Walmart, are prime long-term investments due to their consistent dividend growth over 50+ years. Coca-Cola offers a 3% yield and strong EBITDA growth, making it a solid buy despite recent stock volatility and health-related headwinds. Johnson & Johnson, despite legal issues, remains undervalued with a 3.2% yield and robust free cash flow, making it an attractive investment.